Top Nephrology Research Papers

Overall: A large, precise randomized-trial meta-analysis supports blood-pressure lowering to prevent major cardiovascular events throughout CKD, but absent absolute effects and harms limit conclusions about net benefit.

Overall: A large randomized trial supports meaningful kidney and possible survival benefits from semaglutide in a highly relevant primary-care population, though the subgroup design and absent safety information limit certainty about net benefit.

Overall: Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis. — Strong pooled randomized evidence shows a precise, moderate reduction in major kidney outcomes with similar overall safety, although absolute benefit and treatment burden are incompletely reported and regimen heterogeneity limits a uniform practice directive.

Overall: This well-conducted US randomised trial found clinically meaningful improvements in dialysis-access function with ATEV, but more interventions, limited follow-up, and unresolved implementation issues reduce its overall impact.

Overall: A clinically relevant systematic review supports several practical strategies for preventing recurrent calcium stones, but low-certainty evidence, absent absolute effects, and important evidence gaps limit confidence and practice-changing impact.

Overall: Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease: The TRACK Randomized Clinical Trial found no cardiovascular benefit and significantly more major bleeding in a rigorous randomized trial, supporting avoidance of this strategy in advanced CKD.

Overall: A large, prespecified pooled analysis found a credible but modest reduction in adjudicated sudden death, with limited absolute-benefit and safety information and only moderate potential to change current practice.

Overall: This large randomized-trial meta-analysis evaluates definitive mortality outcomes and supports cardiovascular mortality benefit, but the neutral all-cause result, absent absolute effects and harms, and exploratory subgroup findings limit its incremental practice impact.

Overall: This well-structured observational study suggests a modest kidney benefit from earlier SGLT-2 inhibitor initiation without detected short-term safety concerns, but residual confounding and the lack of mortality or cardiovascular benefit limit immediate practice-changing certainty.

Overall: This multicenter US observational study links RAAS inhibition to clinically important renal benefits, but residual confounding, absent absolute benefit and harm data, and the specialized pediatric CKD population limit its impact on routine primary care.